ORLANDO, Fla.--(BUSINESS WIRE)--Adverse events (AEs), or side effects, have traditionally been viewed as an unavoidable consequence in the therapeutic treatment of cancer patients. Yet sufficient data exists to study the relationship between molecular mechanisms, and drug-induced phenotypes to learn about – and even predict – adverse events in patients.
